Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.68+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Celldex aims to keep enough cash to fund operations through 2028. It focuses on managing operating losses, which were -$84.4M in 2026-Q1. Analysts expect revenue to improve from about $2.6B in 2026 to $11.96B in 2027. The stock price has risen 33% in the last 21 days, showing growing investor interest.
The company has missed earnings repeatedly, showing ongoing losses. Revenue is expected to decline sharply by 60% next year. Operating losses remain large and unmanaged. Cash flow is negative, raising doubts about sustaining operations through 2028.
The market prices in about a 60% revenue decline next year and expects continued losses. The stock trades about 14% below our estimate of its value based on current forecasts. Our view differs by expecting some recovery in revenue and better loss management.
Breaks if: Cash reserves fall below levels needed to fund operations through 2028
Breaks if: Operating losses worsen or remain at or below -$84M over next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, focusing on clinical advancements and potential commercialization. The current thesis state is cautious, as recent performance has been neutral compared to industry peers.
The market seems to have low expectations for fragility, as no significant risks are currently priced in. However, the valuation reflects that CLDX is still considered loss-making, which suggests that investors are cautious about its path to profitability.
Management is on track with key priorities, including advancing barzolvolimab Phase 3 trials and maintaining sufficient cash to fund operations through 2028. However, the mixed status of the CDX-622 program and the moderate risk level indicate that performance could fluctuate.
The thesis hinges on the outcomes of ongoing clinical trials and the overall performance of the healthcare sector. Key scenarios include the impact of guidance changes and broader economic conditions affecting healthcare stocks.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $2.6B in FY26 or fails to grow toward $11.96B in FY27
Over the next 1 to 3 years, CLDX's success will depend on its clinical progress and market conditions. Not investment advice.